9 completed, 3 terminated. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 9, Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Sumitomo Pharma Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan SEP-363856 - Schizophrenia | Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 68 | 2022-05-16 | 2025-03-19 |
| A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase SEP-363856 50 mg, SEP-363856 75 mg, Placebo - Schizophrenia | Phase 2 / Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 83 | 2021-03-29 | 2024-03-15 |
| Confirmatory Study of DSP-5423P in Patients With Schizophrenia DSP-5423P Placebo, DSP-5423P 40mg, DSP-5423P 80mg - Schizophrenia | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 580 | 2014-12-01 | 2022-04-12 |
| Long-term Study of DSP-5423P in Patients With Schizophrenia DSP-5423P - Schizophrenia | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 200 | 2014-12-01 | 2022-04-12 |
| A Phase III Study of SM-13496 in Patients With Bipolar I Depression. Placebo, SM-13496 - Bipolar Depression | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 525 | 2014-02-19 | 2022-04-12 |
| A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. SM-13496 - Bipolar I Disorder | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 495 | 2014-01-29 | 2022-04-12 |
| Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia SM-13496 - Schizophrenia | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 284 | 2012-08-01 | 2022-04-12 |
| A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia SM-13496 40mg, SM-13496 80mg, Placebo - Schizophrenia | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 457 | 2012-07-02 | 2022-04-12 |
| Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer Amrubicin hydrocloride, Docetaxel - Lung Cancer | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 202 | 2010-10-01 | 2022-04-12 |
| Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia SM-13496 (lurasidone HCl), Placebo, Risperidone - Schizophrenia | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 460 | 2008-06-27 | 2022-04-12 |
| Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) Amrubicin Hydrochloride - Small-cell Lung Cancer | Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 130 | 2006-04-01 | 2022-04-12 |
| Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy ranirestat, (AS-3201) - Diabetic Neuropathy | Phase 3 | Completed | Sumitomo Pharma Co., Ltd. | 500 | 2004-10-01 | 2008-01-14 |
Schizophrenia (7) · Bipolar Disorder (1) · Diabetic Neuropathies (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Lurasidone Hydrochloride (5) · SEP-363856 (2) · Docetaxel (1) · Risperidone (1) · amrubicin (1) · ranirestat (1)
Japan (11) · Taiwan (7) · Malaysia (5) · Philippines (4) · South Korea (4) · Russia (3) · Ukraine (3) · China (2) · Lithuania (2) · Slovakia (2) · Canada (1)
PMID 19366965, PMID 28426104, PMID 31883082, PMID 32827348, PMID 32902200, PMID 33321381, PMID 34342746, PMID 36369028, PMID 36632763, PMID 39098761, PMID 39428614